AAAAAA

   
Results: 1-11 |
Results: 11
Assays to predict the genotoxicity of the chromosomal mutagen etoposide - focussing on the best assay
Authors: Turner, SD Wijnhoven, SWP Tinwell, H Lashford, LS Rafferty, JA Ashby, J Vrieling, H Fairbairn, LJ
Citation: Sd. Turner et al., Assays to predict the genotoxicity of the chromosomal mutagen etoposide - focussing on the best assay, MUT RES-GTE, 493(1-2), 2001, pp. 139-147
Development of synthetic promoters for radiation-mediated gene therapy
Authors: Marples, B Scott, SD Hendry, JH Embleton, MJ Lashford, LS Margison, GP
Citation: B. Marples et al., Development of synthetic promoters for radiation-mediated gene therapy, GENE THER, 7(6), 2000, pp. 511-517
A radiation-controlled molecular switch for use in gene therapy of cancer
Authors: Scott, SD Marples, B Hendry, JH Lashford, LS Embleton, MJ Hunter, RD Howell, A Margison, GP
Citation: Sd. Scott et al., A radiation-controlled molecular switch for use in gene therapy of cancer, GENE THER, 7(13), 2000, pp. 1121-1125
Enhancing hemopoietic drug resistance: A rationale for reconsidering the clinical use of mitozolomide
Authors: Fairbairn, LJ Chinnasamy, N Lashford, LS Chinnasamy, D Rafferty, JA
Citation: Lj. Fairbairn et al., Enhancing hemopoietic drug resistance: A rationale for reconsidering the clinical use of mitozolomide, CANC GENE T, 7(2), 2000, pp. 233-239
The effects of dose, route of administration, drug scheduling and MDR-1 gene transfer on the genotoxicity of etoposide in bone marrow
Authors: Turner, SD Rafferty, JA Fairbairn, LJ Ashby, J Tinwell, H Eckert, HG Baum, C Lashford, LS
Citation: Sd. Turner et al., The effects of dose, route of administration, drug scheduling and MDR-1 gene transfer on the genotoxicity of etoposide in bone marrow, LEUKEMIA, 14(10), 2000, pp. 1796-1802
The expression of full length Gp91-Phox protein is associated with reducedamphotropic retroviral production
Authors: Bellantuono, I Lashford, LS Rafferty, JA Fairbairn, LJ
Citation: I. Bellantuono et al., The expression of full length Gp91-Phox protein is associated with reducedamphotropic retroviral production, HAEMATOLOG, 85(5), 2000, pp. 451-457
Engineering drug resistance in human cells
Authors: Fairbairn, LJ Rafferty, JA Lashford, LS
Citation: Lj. Fairbairn et al., Engineering drug resistance in human cells, BONE MAR TR, 25, 2000, pp. S110-S113
A novel dual function retrovirus expressing multidrug resistance 1 and O-6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents
Authors: Jelinek, J Rafferty, JA Cmejla, R Hildinger, M Chinnasamy, D Lashford, LS Ostertag, W Margison, GP Dexter, TM Fairbairn, LJ Baum, C
Citation: J. Jelinek et al., A novel dual function retrovirus expressing multidrug resistance 1 and O-6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents, GENE THER, 6(8), 1999, pp. 1489-1493
Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy
Authors: Chinnasamy, N Rafferty, JA Lashford, LS Chinnasamy, D Margison, GP Thatcher, N Dexter, TM Fairbairn, LJ
Citation: N. Chinnasamy et al., Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy, LEUKEMIA, 13(11), 1999, pp. 1776-1783
Leptomeningeal melanoma in childhood
Authors: Makin, GWJ Eden, OB Lashford, LS Moppett, J Gerrard, MP Davies, HA Powell, CVE Campbell, AN Child, HF
Citation: Gwj. Makin et al., Leptomeningeal melanoma in childhood, CANCER, 86(5), 1999, pp. 878-886
Ifosfamide/etoposide alternating with high dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma
Authors: Michelagnoli, MP Lewis, IJ Gattamaneni, HR Bailey, CC Lashford, LS
Citation: Mp. Michelagnoli et al., Ifosfamide/etoposide alternating with high dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma, BR J CANC, 79(7-8), 1999, pp. 1174-1178
Risultati: 1-11 |